Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

24 Mar 2010 11:52

RNS Number : 1022J
Piper Jaffray Ltd
24 March 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

Piper Jaffray Ltd.

Company dealt in

Ark Therapeutics Group plc 

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ord 1p

Date of dealing

23 March 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

210,196 0.10%

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

210,196 0.10%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

 

(c) Rights to subscribe (Note 2)

 

Class of relevant security:

 

Details

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 4)

Buy

10,000

11.50p

Buy

10,000

11.75p

Buy

10,000

12.00p

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

 

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

(d) Other dealings (including new securities) (Note 3)

 

Nature of transaction (Note 7)

 

Details

Price per unit (if applicable) (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

 

 

Date of disclosure

24 March 2010

Contact name

Norman Gould

Telephone number

020 3142 8780

Name of offeree/offeror with which connected

Ark Therapeutics Group plc 

Nature of connection (Note 9)

Adviser and broker

 

 

Notes

 

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMUSVARRRAOUAR
Date   Source Headline
13th Jul 200610:26 amRNSHolding(s) in Company
27th Jun 20063:34 pmRNSHolding(s) in Company
21st Jun 20067:01 amRNSRe Agreement
9th Jun 20061:58 pmRNSHolding(s) in Company
5th Jun 20063:44 pmRNSBlocklisting Interim Review
22nd May 20063:52 pmRNSDirectors' Shareholdings
19th May 20063:13 pmRNSRe Placing and Open Offer
27th Apr 20063:29 pmRNSResult of AGM
27th Apr 20067:03 amRNSPlacing and Open Offer
30th Mar 20067:01 amRNSRe Agreement
28th Mar 20063:22 pmRNSAnnual Information Update
9th Mar 20067:02 amRNSFinal Results
24th Feb 20064:44 pmRNSOption Awards
15th Feb 20067:01 amRNSRe Agreement
9th Feb 200611:18 amRNSDirector Share Dealing
19th Jan 200611:12 amRNSNotice of Results
16th Jan 20067:01 amRNSResearch Update
12th Jan 20067:00 amRNSUS Patent for Kerraboot
3rd Nov 20057:01 amRNSGrant for New Facility
28th Oct 20057:01 amRNSResearch Update
28th Oct 20057:01 amRNSRegulatory Application
28th Oct 20057:01 amRNSResearch Update
20th Oct 20057:00 amRNSArk Granted Licence
18th Oct 20057:00 amRNSResearch Update
5th Oct 20057:00 amRNSoxLDL approval
13th Sep 20054:37 pmRNSHolding(s) in Company
9th Sep 20055:00 pmRNSHolding(s) in Company
9th Sep 20053:46 pmRNSHolding(s) in Company
31st Aug 20057:01 amRNSInterim Results
24th Aug 20055:56 pmRNSHolding(s) in Company
5th Aug 20057:00 amRNSResearch Update
29th Jul 20056:00 pmRNSHolding(s) in Company
28th Jul 20053:48 pmRNSNotice of Results
25th Jul 20055:28 pmRNSInterest in Shares
21st Jul 20057:01 amRNSResearch Update
7th Jul 20057:00 amRNSBoard Appointment
23rd Jun 20058:41 amRNSDirector Shareholding
21st Jun 20057:00 amRNSResearch Update
14th Jun 20057:00 amRNSSigns Marketing Deal
8th Jun 20054:41 pmRNSListing Applications
7th Jun 20053:40 pmRNSHolding(s) in Company
19th May 20057:00 amRNSKerraboot Marketing Deal
4th May 20057:00 amRNSStrengthened Patent Position
3rd May 20056:11 pmRNSHolding(s) in Company
28th Apr 20054:25 pmRNSDoc re. Result of AGM
14th Apr 20057:00 amRNSResearch Update
7th Apr 20057:00 amRNSAppointment
1st Apr 20052:43 pmRNSNotice of AGM
1st Apr 20057:00 amRNSRe Agreement
23rd Mar 20057:00 amRNSResearch Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.